EFPIA debuts tendering process for Medicines Verification System

12 April 2012

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the official launch of the tendering process for key components of its European Medicines Verification System (EMVS) as of April 5, 2012.

The EFPIA plans to prove the efficiency and to demonstrate the viability of the EMVS through real-life implementation ahead of the publication of the European Commission’s Delegated Act on Safety Features (expected by 2014). The stakeholder-governed solution proposed by the EFPIA and its partners in the pharmaceutical supply chain is indeed likely to constitute the key solution for future implementation of the Falsified Medicines Directive.

The EMVS will consist of the following key components:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >